Safety

GLP-1 Side Effects: What Is Expected and What Needs a Clinician

Gastrointestinal effects — nausea, diarrhoea, constipation, vomiting, abdominal pain — are common, usually mild to moderate, and concentrated during dose escalation. Seve

What the trials recorded

In SURMOUNT-1 at the 15 mg dose: nausea in 29% of participants, diarrhoea 23%, constipation 17%, vomiting 13%, dyspepsia 10%. Most were mild to moderate and clustered during dose escalation rather than at steady state.

Discontinuation because of an adverse event ranged from 4.3% to 7.1% across doses, against 2.6% on placebo. Roughly one in fourteen people at the top dose stopped because they could not tolerate it.

What the label flags as serious

These are from the Zepbound prescribing information rather than from patient forums, and the distinction matters.

• Boxed warning: thyroid C-cell tumours. Observed in rats; human relevance not determined. Contraindicated with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2.
• Serious hypersensitivity. Anaphylaxis and angioedema have been reported. Contraindicated with known serious hypersensitivity to tirzepatide or its excipients.
• Acute gallbladder disease. Reported in clinical trials. If cholecystitis is suspected, the label directs gallbladder studies and clinical follow-up.
• Pancreatitis. Severe abdominal pain, often radiating to the back and sometimes with vomiting, warrants urgent assessment.
• Pregnancy. May cause fetal harm.

The label also states that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended — directly relevant if you are considering a compounded product alongside a branded one.

The line between expected and urgent

Expected, and usually improving: nausea in the days after a dose increase, reduced appetite, constipation, early fullness, fatigue during escalation.

Contact your prescriber: vomiting that prevents fluids, symptoms that do not settle between doses, dizziness on standing, or anything that makes you consider stopping.

Urgent, same day: severe abdominal pain especially radiating to the back; swelling of face, lips or tongue or difficulty breathing; persistent vomiting with dehydration; severe right-upper abdominal pain with fever or jaundice.

This is a guide to when to seek help, not a substitute for seeking it. If you are unsure, contact a clinician.

Why escalation speed matters more than most programmes admit

The label directs increases in 2.5 mg increments no sooner than every four weeks, based on tolerability and response. That is a minimum interval, not a schedule, and there is nothing requiring anyone to reach 15 mg — the recommended maintenance dosages are 5, 10 and 15 mg.

A programme escalating on a fixed calendar without assessing tolerability is not following the label's logic. If side effects are difficult, slowing down or holding at a lower dose is a legitimate clinical option, and worth raising rather than enduring.

What we will not do on this page

Suggest remedies. Managing nausea, hydration and bowel habit during treatment involves individual factors — your other medications, your kidney function, your history — that a website cannot see. Those belong with the clinician who prescribed the medication, and if that person is hard to reach, that is itself information about the programme.

Report side effects to your prescriber and to FDA MedWatch.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.